Results 121 to 130 of about 9,592 (241)
Evolución de los pacientes infectados por el virus de la hepatitis C tratados con antivirales de acción directa en Álava. Durante el período 2015-2017. [PDF]
, 2018 [ES] La infección por el virus de la hepatitis C (VHC) en la población general se caracteriza por una evolución crónica y, en general, benigna, tal como demuestran los estudios epidemiológicos prospectivos y retrospectivos.
Gil González, Cristina
core
Head-to-head clinical Trial of Sofosbuvir plus Daclatasvir or Simeprevir for 12 weeks in Non-cirrhotic subjects with significant fibrosis infected with chronic Hepatitis C Virus genoType 1 (TNT-1 Study) [PDF]
, 2018 Henrique Pott +4 more
openalex +1 more source
ImmunoDendritic cells (DCs) play a crucial role in controlling viral infections. Little is known about the changes in frequencies of the DC subsets in patients with chronic hepatitis C (CHC), particularly in the era of interferon-free regimens.
Helal F. Hetta +9 more
doaj +1 more source
Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection [PDF]
, 2015 Chalermrat Bunchorntavakul +1 more
openalex +1 more source
History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C [PDF]
, 2015 The development of antiviral drugs is a very complex process. Currently, around 50 drugs have been approved for human use against viruses such as HSV, HIV-1, the cytomegalo virus, the influenza virus, HBV and HCV.
Barrera Saldaña, Hugo Alberto +5 more
core
Therapeutics and Clinical Risk Management, 2017 Jan Sperl,1 Sona Frankova,1 Miluse Kreidlova,2 Dusan Merta,3 Monika Tothova,4 Julius Spicak1 1Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 2Institute of Medical Biochemistry and Laboratory Medicine, General ...
Sperl J +5 more
doaj